Launch of Insilico Medicine’s AI and Quantum Computing R&D Center in Abu Dhabi
L to R: Dr. Alex Aliper, Co-founder and President of Insilico Medicine; Dr. Eric Xing, President of MBZUAI; H.E. Dr. Mariam Matar, MD, PhD, Founder and Chairperson of the UAE Genetic Ailments Affiliation; Ahmed Baghoum, Performing CEO of Masdar Metropolis; Eng. Abdulla Abdul Aziz AlShamsi, Performing Director Common of the Abu Dhabi Funding Workplace; Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine.
Abu Dhabi, Feb. 01, 2023 (GLOBE NEWSWIRE) — Insilico Medicine (“Insilico”), a clinical-stage synthetic intelligence (AI)-driven drug discovery firm, is saying in the present day the opening of the Insilico Medicine Generative Synthetic Intelligence and Quantum Computing Research and Growth Center in Abu Dhabi, the area’s largest AI-powered biotechnology analysis middle.
Positioned in the Worldwide Renewable Power Company (IRENA) headquarters in Masdar Metropolis, Abu Dhabi’s flagship sustainable city growth, the analysis and growth (R&D) hub will comprise international expertise in synthetic intelligence and software program growth devoted to increasing the capabilities of Insilico’s end-to-end AI-driven drug discovery platform, Pharma.AI, exploring growing old analysis and sustainable chemistry, and supporting the digital transformation of healthcare in the area.
The grand opening occurred at the IRENA headquarters atrium in Masdar Metropolis, witnessed by practically 100 ecosystem companions from the authorities, academia, the funding group, and the AI and biotech trade. The occasion featured speeches from H.E. Omar Al Olama, the Minister of State for Synthetic Intelligence, Digital Financial system and Distant Work Functions, Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico, and Alex Aliper, Ph.D., President of Insilico.
“The prime location, strong and stable economy, developed infrastructure, and highly educated talent make Abu Dhabi an emerging hub that attracts high-tech companies from around the world. We are excited to be a part of this,” mentioned Alex Aliper, Ph.D., President of Insilico, who will function the regional hub’s basic supervisor. “We plan to hire locally and work closely with biotech companies and academic partners to license Insilico’s proprietary software and collaborate on joint research projects to facilitate the digital transformation of the local healthcare industry.”
“This is exactly the kind of groundbreaking work in artificial intelligence that we aim to support in our free zone and innovation ecosystem,” mentioned Ahmed Baghoum, the performing CEO of Masdar Metropolis. “We’re excited about this milestone for Insilico Medicine — particularly given it is taking place during the Year of Sustainability. We look forward to the transformational research that will certainly come out of this incredible new hub, and we thank the Abu Dhabi Investment Office for attracting these kinds of organizations to Masdar City.”
Insilico has made regular inroads into the Middle East. On January 31, 2023, the Firm introduced that it’ll obtain assist from the Abu Dhabi Funding Workplace (ADIO) to determine its regional HQ in Abu Dhabi centered on R&D for its AI platform. Eng. Abdulla Abdul Aziz AlShamsi, Performing Director Common of the Abu Dhabi Funding Workplace, mentioned: “ADIO congratulates Insilico Medicine on the opening of a regional HQ in the UAE capital. Abu Dhabi has made it a priority to advance technological solutions that further economic progress for the region and beyond. Insilico Medicine is a stellar example of the success of that strategy, and proof of the limitless opportunities available for health tech companies in Abu Dhabi.”
In August 2022, the Firm introduced a Collection D2 funding led by Prosperity7 Ventures, the diversified development fund of Aramco Ventures, increasing its AI biotechnology experience into Saudi Arabia. The corporate additionally signed a Memorandum of Understanding with the Ministry of Funding of Saudi Arabia, which incorporates offering Insilico’s end-to-end AI drug discovery platform to native biotech corporations, partnering with native biotechs on robotic drug discovery, contributing to native scientific trial experience, and additional growing initiatives extending wholesome and productive longevity.
Insilico founder and CEO Alex Zhavoronkov, Ph.D., was additionally a featured speaker at the World AI Summit in Riyadh, Saudi Arabia, in Sept. 2022, an occasion centered on AI for the good of humanity.
“Since our very inception, our mission has been to extend healthy, productive longevity for everyone on the planet. Over the past decade, we developed a platform for drug discovery and longevity and became one of the dominant companies in this field. Now, we would like to extend our global infrastructure to the Middle East,” mentioned Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. “We look forward to expanding our presence and connections in the region by creating a true AI drug discovery hub in Abu Dhabi.”
About Insilico Medicine
Insilico Medicine, a clinical-stage end-to-end synthetic intelligence (AI)-driven drug discovery firm, connects biology, chemistry, and scientific trials evaluation utilizing next-generation AI methods. The corporate has developed AI platforms that make the most of deep generative fashions, reinforcement studying, transformers, and different trendy machine studying strategies to find novel targets and design novel molecular constructions with desired properties. Insilico Medicine delivers breakthrough options to find and develop progressive medicine for most cancers, fibrosis, immunity, central nervous system (CNS), and aging-related ailments.
For extra data, go to www.insilico.com
For media inquiries, please contact firstname.lastname@example.org
AttachmentCONTACT: Brita Belli Insilico Medicine 475-225-0843 email@example.com